Fig. 6: Carboplatin and paclitaxel do not inhibit metastasis in patient-derived ZTX models of EOC.
From: Zebrafish tumour xenograft models: a prognostic approach to epithelial ovarian cancer
a, b Comparison of changes in average number of disseminated cells (rel. number of metastasized cells) between vehicle and treatment with either carboplatin (10 μg/mL) (a) and paclitaxel (20 μg/mL) (b) in samples from either primary tumours or from metastatic lesions. Patients with a progression-free survival (PFS) of less than 24 months are indicated with a red bar. Dissemination in non-treated controls (100%) is indicated by the blue dashed line. All experiments were done once. *p < 0.05, **p < 0.01, ***p < 0.001. Pat: patient.
